QuidelOrtho Corporation

QDEL - Financial Snapshot

Metrics for QDEL

Price $15.24
Shares Outstanding 68.08M
All-Time Low $1.69
52-Week Low $19.50

Balance Statement Metrics

Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
Net Current Assets / Share $-35.27
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
Net Tangible Assets / Share $0
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
Shares Outstanding Ave Change (Annual) 17.29%
Shares Δ YoY 0.83%
Avg CA Burn (Annual %) -4.81% (as of 3-8-2026)
Avg CA Burn (Quarterly %) 4.41% (as of 3-8-2026)

Earning Metrics

Max Earning Power / Share $7.02
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
Adjusted Earning Power $-18.28
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
Non-Cash Charges to Market Cap 9.66%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Avg EBITDA (5Y) 663.6M (as of 3-8-2026)
Avg EBITDA (5Q) 40.8M (as of 3-8-2026)
Avg Net Income (5Y) -202.3M (as of 3-8-2026)
Avg Net Income (5Q) -262M (as of 3-8-2026)
Data as of: Price 03-20-26 16:00 ET, Balance Sheet 2025-12-31, Income Statement 2025-12-31, Cash Flow 2025-12-31

Indicators

Dividend indicators Value Date
Current Dividend Streak No 3-8-2026
Consecutive Years Paid No 3-8-2026
Pays Dividend No 3-8-2026
Income indicators Value Date
EBITDA Positive Yes 3-8-2026
Net Income Positive No 3-8-2026
Current Dividend Streak No 3-8-2026

Metric History Explorer

Pick a metric to view its history table and chart.

Tangible Book Value Per Share History

Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.

Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).

Report Date Period TBV / Share Tangible Book Value Shares Used
2025-12-31 Quarterly $-9.47 -643.3M ($-643,300,000) 67.9M (67,931,540)
2025-09-30 Quarterly $-8.42 -571.6M ($-571,600,000) 67.9M (67,900,466)
2025-06-30 Quarterly $-8.55 -578.9M ($-578,900,000) 67.7M (67,700,000)
2025-03-31 Quarterly $-5.51 -371.6M ($-371,600,000) 67.5M (67,454,614)
2024-12-31 Quarterly $-5.96 -400.6M ($-400,600,000) 67.3M (67,256,717)
2024-12-31 Annual $-5.96 -400.6M ($-400,600,000) 67.3M (67,256,717)
2024-09-30 Quarterly $-5.65 -379.8M ($-379,800,000) 67.2M (67,235,394)
2023-12-31 Annual $-6.30 -420.4M ($-420,400,000) 66.7M (66,700,000)
2022-12-31 Annual $-10.03 -666M ($-666,000,000) 66.4M (66,400,000)
2021-12-31 Annual $35.83 1.5B ($1,493,700,000) 41.7M (41,686,000)

Dividend Payments

Historical cash dividends per share from Yahoo ex-dividend dates.

Date Dividend / Share
No dividend payment history available yet

Shares Outstanding Changes

Date Shares Outstanding Delta
2026-03-03 68,081,767 +150,227
2025-11-10 67,931,540 +31,074
2025-09-17 67,900,466 -30
2025-08-08 67,900,496 +274,592

Short Interest Changes

Latest short-interest change: 10,302,587 shares (25.10% of float) | Days to cover: 8.09

Date Short Interest Delta Δ %
2026-03-12 10,302,587 shares +120,372 +1.18%
2026-02-27 10,182,215 shares -189,092 -1.82%
2026-02-11 10,371,307 shares -149,612 -1.42%

Interesting Volume Days

Volume/ratio use shares outstanding as of the event date (frozen).

Date Volume Shares Outstanding Volume / Shares Price
No interesting volume events

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.